Vol. 5 No. 11 (2025)
Reimbursement Reviews

Omaveloxolone (Skyclarys)

decorative image of the issue cover

Published November 28, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses omaveloxolone (Skyclarys), administered at a recommended dose of 150 mg orally once daily (3 capsules of 50 mg each).
  • Indication: For the treatment of Friedreich’s ataxia in patients aged 16 years or older.